1. Scrip
  2. >>Focus On Asia
  3. >>China

Competition and Price Cuts Slow Strong IO Momentum In China

 
• By Dexter Jie Yan

While strong growth in China's immuno-oncology sector continued in the last quarter, the momentum appears to be slowing, affecting by multiple factors including intense competition in the sector and price cuts related to reimbursement listing, while regulatory authorities have already warned about what they see as the wasting of resources on "redundant" development activities. 

Chinese biotechs posted slower growths in sales of PD-1 agents.
Chinese biotechs posted slower growths in 3Q sales of PD-1 agents. • Source: Alamy

The last fiscal quarter has not been hot for immuno-oncology developers in China, which have reported generally sluggish performances as new players entered the already competitive field and prices fell further.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia